Literature DB >> 31648942

Resolving complexity in mitochondrial disease: Towards precision medicine.

Róisín M Boggan1, Albert Lim1, Robert W Taylor1, Robert McFarland2, Sarah J Pickett1.   

Abstract

Mitochondrial diseases, caused by mutations in either the nuclear or mitochondrial genomes (mtDNA), are the most common form of inherited neurometabolic disorders. They are remarkably heterogeneous, both in their clinical presentation and genetic etiology, presenting challenges for diagnosis, clinical management and elucidation of molecular mechanism. The multifaceted nature of these diseases, compounded by the unique characteristics of mitochondrial genetics, cement their space in the field of complex disease. In this review we examine the m.3243A>G variant, one of the most prevalent mitochondrial DNA mutations, using it as an exemplar to demonstrate the challenges presented by these complex disorders. Disease caused by m.3243A>G is one of the most phenotypically diverse of all mitochondrial diseases; we outline known causes of this heterogeneity including mtDNA heteroplasmy, mtDNA copy number and nuclear genetic factors. We consider the impact that this has in the clinic, discussing the personalized management of common manifestations attributed to this pathogenic mtDNA variant, including hearing impairment, diabetes mellitus, myopathy, cardiac disease, stroke-like episodes and gastrointestinal disturbances. Future research into this complex disorder must account for this heterogeneity, benefitting from the use of large patient cohorts to build upon current clinical expertise. Through multi-disciplinary collaboration, the complexities of this mitochondrial disease can be addressed with the variety of diagnostic, prognostic, and treatment approaches that are moulded to best fit the needs of each individual patient.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complex disease; Heterogeneity; MELAS; Mitochondrial disease; Precision medicine; m.3243A>G

Mesh:

Substances:

Year:  2019        PMID: 31648942     DOI: 10.1016/j.ymgme.2019.09.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  A conceptual disease model for quality of life in mitochondrial disease.

Authors:  Kim F E van de Loo; Nander T van Zeijl; Mirian C H Janssen; Christianne M Verhaak; José A E Custers
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

Review 2.  The Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics.

Authors:  Sanjana Saravanan; Caitlin J Lewis; Bhavna Dixit; Matthew S O'Connor; Alexandra Stolzing; Amutha Boominathan
Journal:  Biomedicines       Date:  2022-02-18

Review 3.  Mitochondrial pathways in human health and aging.

Authors:  Rebecca Bornstein; Brenda Gonzalez; Simon C Johnson
Journal:  Mitochondrion       Date:  2020-07-30       Impact factor: 4.160

Review 4.  DECIPHER: Supporting the interpretation and sharing of rare disease phenotype-linked variant data to advance diagnosis and research.

Authors:  Julia Foreman; Simon Brent; Daniel Perrett; Andrew P Bevan; Sarah E Hunt; Fiona Cunningham; Matthew E Hurles; Helen V Firth
Journal:  Hum Mutat       Date:  2022-02-21       Impact factor: 4.700

5.  Varied Responses to a High m.3243A>G Mutation Load and Respiratory Chain Dysfunction in Patient-Derived Cardiomyocytes.

Authors:  Sanna Ryytty; Shalem R Modi; Nikolay Naumenko; Anastasia Shakirzyanova; Muhammad Obaidur Rahman; Miia Vaara; Anu Suomalainen; Pasi Tavi; Riikka H Hämäläinen
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

6.  Peculiarities of the m.3243A>G variant in MT-TL1 leave medicine unprecise.

Authors:  Josef Finsterer
Journal:  Mol Genet Metab Rep       Date:  2019-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.